BLPH VS SYRA Stock Comparison

Performance

BLPH
10/100

BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.

SYRA
10/100

SYRA returned -63.43% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

BLPH
75/100

1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

SYRA

"Analyst Price Targets" not found for SYRA

Technicals

BLPH
11/100

BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

SYRA

"Technicals" not found for SYRA

Earnings

BLPH
36/100

BLPH has missed earnings 3 times in the last 20 quarters.

SYRA

"Earnings" not found for SYRA

Profit

BLPH
10/100

Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.

SYRA

"Profit" not found for SYRA

Volatility

BLPH
57/100

BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

SYRA
33/100

SYRA has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Bellerophon Therapeutics, Inc. Summary

Nasdaq / BLPH

Healthcare

Biotechnology

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Syra Health Corp. Class A Common Stock Summary

Nasdaq / SYRA

Healthcare

Medical - Care Facilities

Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.

Power up your portfolio